Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2002-01-18
2010-06-29
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S172100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750, C435S007100, C435S007240
Reexamination Certificate
active
07744888
ABSTRACT:
Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
REFERENCES:
patent: 5378464 (1995-01-01), McEver
patent: 5618785 (1997-04-01), Heavner et al.
patent: 5709859 (1998-01-01), Aruffo et al.
patent: 5710123 (1998-01-01), Heavner et al.
patent: 5808025 (1998-09-01), Tedder et al.
patent: 5827817 (1998-10-01), Larsen et al.
patent: 5834425 (1998-11-01), Tedder et al.
patent: 5840679 (1998-11-01), Larsen et al.
patent: 5843707 (1998-12-01), Larsen et al.
patent: 5852175 (1998-12-01), Cummings et al.
patent: 5972625 (1999-10-01), Rosen et al.
patent: 6056956 (2000-05-01), Cobbold et al.
patent: 6124267 (2000-09-01), McEver et al.
patent: 6309639 (2001-10-01), Cummings et al.
patent: 6667036 (2003-12-01), Cummings et al.
patent: 2002/0164336 (2002-11-01), Harrison et al.
patent: 2004/0002450 (2004-01-01), Lazarovits et al.
patent: 2005/0152906 (2005-07-01), Levanon et al.
patent: 09-227410 (1997-09-01), None
patent: WO 97/06176 (1997-02-01), None
patent: WO 00/25808 (2000-05-01), None
patent: WO 02/053700 (2002-07-01), None
Trembleau et al. J. Immunol. 163: 2960-2968, 1999.
Yago et al., J. Immunol. 161: 1140-1145, 1998.
Chen et al., Blood 104: 3233-3242, 2004.
Borges et al., “The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin Is Differentially Regulated,” Journal of Biological Chemistry 272(45):28786-28792 (Nov. 7, 1997).
Borges et al., “P-Selectin Glycoprotein Ligand-1 (PSGL-1) on T Helper 1 but Not on T Helper 2 Cells Binds to P-Selectin and Supports Migration into Inflamed Skin,” J. Exp. Med. 185(3):573-578 (Feb. 3, 1997).
Evangelista et al., “Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation-Dependent CD11b/CD18 Adhesion: Role of PSGL-1 as a Signaling Molecule,” Blood 93(3):876-885 (Feb. 1, 1999).
Faraday et al., “Leukocytes Can Enhance Platelet-mediated Aggregation and Thromboxane Release via Interaction of P-selectin Glycoprotein Ligand 1 with P-selectin,” Anesthesiology 94(1):145-151 (Jan. 2001).
Frenette et al., “P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vivo,” J. Exp. Med. 191(8):1413-1422 (Apr. 17, 2000).
Fuhlbrigge et al., “Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells,” Nature 389:978-981 (Oct. 1997).
Hirata et al., “P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is a Physiological Ligand for E-Selectin in Mediating T Helper 1 Lymphocyte Migration,” J. Exp. Med. 192(11):1669-1675 (Dec. 4, 2000).
Hirose et al., “A functional epitope on P-selectin that supports binding of P-selectin to P-selectin glycoprotein ligand-1 but not to sialyl Lewis X oligosaccharides,” International Immunology 10(5):639-649 (Jan. 26, 1998).
Laszik et al., “P-Selectin Glycoprotein Ligand-1 Is Broadly Expressed in Cells of Myeloid, Lymphoid, and Dendritic Lineage and in Some Nonhematopoietic Cells,” Blood 88(8):3010-3021 (Oct. 15, 1996).
Levesque et al., “PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematopoiesis,” Immunity 11:369-378 (Sep. 1999).
Snapp et al., “A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin,” Blood 91(1):154-164 (Jan. 1, 1998).
Yang et al., “Targeted Gene Disruption Demonstrates That P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Required for P-Selectin-mediated but Not E-Selectin-mediated Neutrophil Rolling and Migration,” J. Exp. Med. 190(12):1769-1782 (Dec. 20, 1999).
Battistini, et al. “CD8+ T cells from 1-37 patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1.”Blood, vol. 101, No. 12, Jun. 15, 2003 (4775-4782).
Diacovo, et al. “Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-seelctin and P-selectin.”J. Exp. Med., vol. 183, Mar. 1996, (1193-1203).
Dimitroff, et al. “Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: Implications in modulating lymphocyte migration to skin.”Blood, vol. 101, No. 2, Jan. 15, 2003 (602-610).
Kaytes, et al. “P-selectin mediates 1-37 adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands.”Biochemistry, vol. 37, No. 29, Jul. 21, 1998 (10514-10521).
Kieffer, et al. “Neutrophilis, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: Cutaneous lymphocyte antigen.”Biochemical and Biophysical Research Communications, vol. 285, No. 3, Jul. 20, 2001 (577-587).
Woltmann, et al. “Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow.”Blood, vol. 95, No. 10, May 15, 2000 (3146-3152).
Beckwith et al., “The Protein Product of the Proto-oncogene c-cbl Forms a Complex With Phosphatidylinositol 3-Kinase p85 and CD19 in Anti-IgM Stimulated Human B-Lymphoma Cells,” Blood 88(9):3502-3507, (1996).
Besnault et al., “B Cell Receptor Cross-Linking Triggers a Caspase-8-Dependent Apoptotic Pathway That Is Independent of the Death Effector Domain of Fas-Associated Death Domain Protein,” The Journal of Immunology, 167:733-740, (2001).
Igarashi et al., “Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor,” Blood, 89(4):1299-1307, (1997).
Shan et al., “Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies,” Blood, 91(5):1644-1652, (1998).
Stockmeyer et al., “Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells,” Journal of Immunology, 171:5124-5129, (2003).
Wing et al., “Mechanism of First-Dose Cytokine-Release Syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK Cells,” J. Clin. Invest., 98(12):2819-2826, (1996).
U.S. Appl. No. 10/662,906, filed Sep. 15, 2003, Rong-Hwa Lin et al.
U.S. Appl. No. 11/125,837, filed May 10, 2005, Rong-Hwa Lin et al.
U.S. Appl. No. 11/127,804, filed May 11, 2005, Rong-Hwa Lin et al.
Nizet Y et al., The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.Transplantation69 (7): 1420-1428 (2000).
Tsukamoto K et al., Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice.Cell. Immunol. 165:193-201 (1995).
Herron MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1.Science. Jun. 2, 2000;288(5471):1653-6.
Li F et al., Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies.J. Biol. Chem. 271(11):6342-6348 (1996).
Moore KL et al., P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin.J. Cell Biol. 128(4):661-671 (1995).
Sako D et al., Expression cloning of a functional glycoprotein ligand for P-selectin.Cell. Dec. 17, 1993;75(6):1179-86.
Trembleau S et al., Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice.J Immunol. Sep. 1, 1999;163(5):2960-8.
Vachino G et al., P-
Hsu Pei-Ling
Lin Rong-Hwa
Wu Chung-Hsiun
AbGenomics Cooperatief U.A.
Gambel Phillip
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods of modulating T cell or natural killer cell activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating T cell or natural killer cell activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating T cell or natural killer cell activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243543